MiNK Therapeutics (INKT)

• Market cap: $28.3M
• 1 day: 4.02%
• 5 days: -10.68%
• 1 month: 3.42%
• 3 months: -13.90%
• 6 months: -29.25%
• Year to date: -34.44%
• 1 year: -32.58%
• 5 years: -94.05%
• 10 years: -94.05%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T-cell therapies to treat cancer and other life-threatening illnesses.

Employees: 37

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

0.45% less ownership

Funds ownership: 2.59% [Q2] → 2.14% (-0.45%) [Q3]

16% less funds holding

Funds holding: 31 [Q2] → 26 (-5) [Q3]

25% less capital invested

Capital invested by funds: $848K [Q2] → $632K (-$216K) [Q3]

29% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 7

56% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 9

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $4 460% upside
• Avg. target: $7.33 926% upside
• High target: $9 1,159% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

Baird Jack Allen 60% 1-year accuracy 6 / 10 met price target	460% upside $4	Outperform Maintained	15 Nov 2024
HC Wainwright & Co. Emily Bodnar 20% 1-year accuracy 24 / 122 met price target	1,159% upside $9	Buy Reiterated	15 Nov 2024
HC Wainwright & Co. Emily Bodnar 20% 1-year accuracy 24 / 122 met price target	1,159% upside $9	Buy Reiterated	9 Oct 2024